Treatment
Cytarabine clinical trials
We’re tracking 156 recruiting studies that include Cytarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT03507842Enrolling by invitationPhase 3
Testing two induction chemo options for newly diagnosed AML
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
SeoulAges 15–60 - NCT03263572RecruitingPhase 2
Study medicines for Philadelphia-positive ALL or relapsed leukemia
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Houston, TexasAges 18 years+ - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT00801489RecruitingPhase 2
New treatment for AML or high-risk MDS using combination chemo
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
Houston, TexasAges 18 years+ - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Sydney, New South WalesAges 1–30 - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT06336395RecruitingPhase 2
ALL treatment study for people under 41
This trial tests a treatment plan for people with a certain type of acute lymphoblastic leukemia (ALL) called B-lineage ALL. It aims to see how well the treatment works and how safe it is.
Kuala LumpurAges Up to 40 years - NCT06520176RecruitingPhase 3
Comparing two stem cell collection methods for multiple myeloma
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
Dongyang, ZhejiangAges 18–75 - NCT06554626RecruitingPhase 2
Study of blinatumomab and venetoclax followed by inotuzumab for B-ALL
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hangzhou, ZhejiangAges 40 years+ - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT07672262RecruitingPhase 2
VA maintenance before transplant for intermediate-risk AML
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
Suzhou, JiangsuAges 18 years+ - NCT06643962Recruiting
Venetoclax plus strong chemo for AML with slow blast clearance
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
Nantong, JiangsuAges 18–70 - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT07563179RecruitingPhase 2
Bugitinib with Venetoclax and Cytarabine for Relapsed AML
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
Shenzhen, GuangdongAges 18–70 - NCT06742463RecruitingPhase 2
VHAG for relapsed or refractory T-cell acute leukemia
This trial tests a combination of drugs (venetoclax, homoharringtonine, cytarabine, and g-CSF, called VHAG) for people whose T-cell acute leukemia or lymphoma has come back or hasn't responded to treatment. It aims to see if this combination can help when other treatments haven't worked.
Hangzhou, ZhejiangAges 14–74 - NCT07537257Enrolling by invitationPhase 2/Phase 3
Venetoclax plus chemotherapy vs chemotherapy alone for acute myeloid leukemia
This trial tests whether adding venetoclax (a targeted drug) to standard chemotherapy helps patients with acute myeloid leukemia (a blood cancer) who have responded well to initial treatment stay cancer-free longer. You would receive the combination or standard therapy alone to see which works better.
Guangzhou, GuangdongAges 18–65 - NCT06741722RecruitingPhase 2
Study of mitoxantrone liposome combo for relapsed or refractory AML
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
BeijingAges 18–75 - NCT07514936RecruitingPhase 3
Venetoclax-Azacitidine With Chidamide and CAG for Older AML Patients
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
Beijing, None SelectedAges 60–75 - NCT07507760RecruitingPhase 2
Oral decitabine plus ivosidenib for older AML patients
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
AveiroAges 18 years+ - NCT07514832RecruitingPhase 2
New chemotherapy combination for untreated acute myeloid leukemia
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
BeijingAges 18–70 - NCT07490288Recruiting
Venetoclax, azacitidine, and mitoxantrone for new AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Tianjin, Tianjin MunicipalityAges 14–100
Common questions
- Are there clinical trials studying Cytarabine?
- Yes. Clin2 currently lists 156 recruiting studies that include Cytarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cytarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cytarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cytarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.